The problem w soli is not the SEC trying to ruin it, though it did go to far last year in its ruling.
As far as I can guess w any educated sense, this is an accounting problem related to a designation of shares made in 2020. Perhaps the sale of clinical herbs?
Honestly I don’t know… but you seem to be implicating something here that is not relevant in my eyes.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.